Brought to you by 
Elan Corp., Isis to form new antisense drug subsidiary
23 Nov 1999
Executive Summary
Elan Corp. PLC and Isis Pharmaceuticals Inc. have signed a letter of intent to form a new subsidiary of Isis which will develop a platform technology for the oral delivery of antisense drugs.
Deal Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan Corp., Isis to form new antisense drug subsidiary
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice